breyanzi
breyanzi: 9 clinical trials tracked.
breyanzi evidence translation
What we can confirm
9 tracked trials
What it means
What to watch
Prepared research question
What is verified about breyanzi, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 2 study sponsors
Clinical Trial Registry Records (9)
Safety and Efficacy of the Addition of Nemtabrutinib to Lisocabtagene Maraleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Primary endpoint: Complete response (CR)
Phase 2 Study of Glofitamab and Gemcitabine and Oxaliplatin (Glofit-GemOx) Bridging to Lisocabtagene Maraleucel in Relapsed/Refractory Aggressive B-cell Lymphomas
Primary endpoint: Complete Response Rate (CRR) to lisocabtagene maraleucel
Non-interventional Cohort Study of Patients Treated With Liso-Cel (Lisocabtagene Maraleucel) for Relapsed/Refractory Marginal Zone Lymphoma in the Postmarketing Setting
Primary endpoint: Incidence and severity of selected adverse events after lisocabtagene maraleucel infusion
A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel , an Autologous, Dual-targeting CD19/CD20 CAR T-Cell Product Candidate, Vs. Investigator's Choice of CD19 CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-Cell Lymphoma in the Second-line Setting
Primary endpoint: Event free survival
A Phase II Study Evaluating the Safety and Efficacy of the Combination of Zanubrutinib Plus Lisocabtagene Maraleucel for Richter's Syndrome
Primary endpoint: Overall response rate
A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma
Primary endpoint: Progression free survival (PFS)
Phase 2 Study of the Combination of Lisocabtagene Maraleucel, Nivolumab, and Ibrutinib in Richter's Transformation
Primary endpoint: Complete Response (CR)
A Phase Ib Open-Label Study Evaluating the Safety and Efficacy of NKTR-255 in Combination With CD19-Directed CAR-T Cell Therapy in Patients With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Primary endpoint: Incidence of adverse events (AEs)
A Phase 1b Study Evaluating the Safety, Tolerability and Preliminary Anti-tumor Activity of NT-I7 a Long-acting Human IL-7, Post-Kymriah®, Post-Yescarta®, or Post-Breyanzi® in Subjects With Relapsed/Refractory Large B-cell Lymphoma
Primary endpoint: Incidence, Nature, and Severity of Adverse Events, Graded According to NCI CTCAE v5.0, Except for Cytokine Release Syndrome (CRS) and Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS), Which Were Graded Based on ASTCT Guidelines